NEW YORK (GenomeWeb News) – KellBenx has licensed antibodies from AdnaGen which it will use to develop non-invasive prenatal diagnostics, AdnaGen's parent company, OncoVista Innovative Therapies said today.
Under the deal, KellBenz will use the antibodies to enrich fetal nucleated red blood cells "to perform chromosomal or genetic analysis to identify markers of potential disorders," OncoVista said in a statement.
FNRBCs have been identified in maternal blood as a possible source for monitoring and diagnosing maternal, fetal, and neonatal health and disease.
KellBenz has exclusive worldwide rights to commercialize AdnaGen's antibodies, called monoclonal antibodies with specificity for fetal erythroid cells, OncoVista said.
Financial terms were not disclosed.